Search Menu
Photonics Media Photonics Marketplace Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook

Pentax Medical Acquires C2 Therapeutics

Facebook Twitter LinkedIn Email Comments
MONTVALE, N.J., Jan. 14, 2017 — Medical imaging equipment manufacturer Pentax Medical has acquired ablation developer C2 Therapeutics for an undisclosed amount.

C2 Therapeutics produces the C2 CryoBalloon Ablation System for the endoscopic ablation of unwanted tissue such as Barrett's esophagus.

"The C2 CryoBalloon Ablation System has the potential to improve the lives of millions of people around the world with pre-cancerous lesions of the esophagus,” said David Woods, global chief marketing officer of Pentax Medical.

Barrett's esophagus and squamous dysplasia are both conditions in which the epithelial cells in the lining of the esophagus abnormally change to form pre-cursor lesions. If left untreated, these lesions can progress to esophageal cancer in some patients. The C2 CryoBalloon Ablation System provides the interventional endoscopist with a means to deliver a targeted dose of cryogen to ablate these tissues immediately. Esophageal cancer is the sixth leading cause of cancer deaths in the world with a five-year survival rate of 18 percent and is the fastest growing form of cancer in the United States today.

Pentax Medical provides endoscopic imaging devices and solutions to the global medical community. C2 Therapeutics is focused on eliminating pre-cancerous conditions and adjunctive treatment in cancer in gastroenterology and pulmonary.
Jan 2017
Pentax MedicalC2 Therapeuticsablationesophagusmergers & acquisitionsAmericasBusinessBiophotonics

view all
Search more than 4000 manufacturers and suppliers of photonics products and services worldwide:

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2021 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, [email protected]

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.